SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)
RIGL 30.42-0.8%10:27 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (467)2/16/2010 10:52:56 AM
From: software salesperson   of 566
 
j. birchenough/r.martins, barclays

Equity Research

February 16, 2010
Rigel Pharmaceuticals (RIGL - US$ 9.43) 1-Overweight
Company Update

Large Pharma Deal Better Than Expected

Investment Conclusion

We are reiterating our 1-Overweight rating on
RIGL following today’s partnership with AZN for
R788 in RA and other rheumatologic disorders.
We believe the deal is one of the best for a biotech
company, with full funding, clear timelines to
commercialization and attractive financial terms.
We believe the deal is better than expected and
would buy RIGL here.

Summary

?? RIGL announced today a global development and
commercialization agreement with Astra Zeneca
for syk kinase inhibitor R788 as well as back up
compounds for rheumatoid arthritis and other
rheumatologic disorders. Terms of the deal
include $100M upfront, $345M in development
milestones, $800M in sales milestones and tiered
double digit royalties that we expect are at the
high end for late stage deals of this type.
?? With AZN funding all development and
commercialization of R788 and back up
compounds, we see significant upside potential for
RIGL here. Expert feedback suggests a
competitive profile for R788 in the $13B RA
market and with phase III initiation in 2H10 and
NDA/EMEA filing expected in 2013 outcomes
study requirements appear unlikely.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext